Therapeutic potential of metallothioneins as antiinflammatory agents in polysubstance abuse

IIOAB Journal

Volumn 2, Issue 6, 2011, Pages 50-61

  Sharma, Sushil ^a   Ebadi, Manuchair ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Alcohol; Cocaine; Coenzyme Q10; Detoxification; Dopamine; Free radicals; Metallothioneins; Methamphetamine; Nicotine; Poly substance abuse; Zinc

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; CAFFEINE; COCAINE; HYDROXYL RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MELATONIN; METALLOTHIONEIN; METHAMPHETAMINE; NICOTINE; OPIATE DERIVATIVE; RECREATIONAL DRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SCAVENGER; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UBIQUINONE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOENERGY; BODY POSTURE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; CROSS BREEDING; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; FENTON REACTION; FETAL STEM CELL; FETUS; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENOTYPE; HIPPOCAMPUS; IN VIVO STUDY; LONGITUDINAL STUDY; METALLOTHIONEIN GENE; MICROGLIA; MITOCHONDRION; MOUSE; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; SUBSTANCE ABUSE; TRANSGENIC MOUSE; WALKING DIFFICULTY;

EID: 84865493364     PISSN: 09763104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Lee YW, Hennig B, Fiala M, Kim KS, Toiborek M. [2001] Cocaine activates redox-regulated transcription factors and induces TNF-alpha expression in human brain endothelial cells. Brain Res 920: 125-133.
2. Lee YW, Son KW, Flora G, Hennig B, Nath A, Toborek M. [2002] Methamphetamine activates DBA binding of specific redox-responsive transcriptional factors I mouse brain. J Neurosci Res 70: 82-89.
3. Tacker DH, Herzog NK, Okorodudu AO. [2006] Cocaethylene affects human microvascular endothelial cell p38 mitogen-activated protein kinase activation and nuclear factor kappa B DNA binding activity. Clin Chem 52: 1926-1933.
4. Borner C, Hollt V, Kraus J. [2002] Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene. Mol Pharmacol 61:800-805.
5. Li Y, Kang J, Friedman J, Tarassishin L, Ye J, Kovalenko A, Wallach D, Horwitz MS. [1999] Identification of a cell protein (FIP-3) as a modulator of NF-kappa-B activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc Natl Acad Sci USA 96: 1042-1047.
6. Altura BM, Gebrewold A. [2002] Inhibitor of nuclear kappa-B activation attenuates venular constriction, leukocyte rolling-adhesion and microvessel rupture induced by ethanol in intact rat brain microcirculation: Relation to ethanol-induced brain injury. Neurosci Lett 334:21-24.
7. Ohkawa H, Sohma H, Sakai R, Kuroki Y, Hashimoto E, Murakami S, Saito T. [2002] Ethanol-induced augmentation of annexin IV in cultured cells and the enhancement of cytotoxicity by overexpression of annexinIV by ethanol. Biochim Biophys Acta 1588: 217-225.
8. Sohma H, Ohkawa H, Sakai R, Hashimoto E, Ukai E, Saito T. [2003] Augmentation of ethanol-induced cell damage and activation of nuclear factor-kappa B by annexin IV in cultured cells. Alcohol Clin Exp Res 27: 64S-67S.
9. Blanco AM, Pascual M, Valles SL, Guerri C. [2004] Ethanol-induced iNOS and COX-2 expression in cultured astrocytes via NF-kappa B. Neuroreport 22:681-685.
10. Zima T, Kalousova M. [2005] Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcoholism: Clin & Exp Res 29: 110S-115S.
11. Crews F, Nixon K, Kim D, Joseph J, Shukitt-hale B, Qin L, Zou J. (2006) BHT blocks NFkappa B activation and ethanol-induced brain damage. Alcohol Clin Exp Res 30:1938-1949.
12. Rulten SL, Ripley TL, Hunt CL, Stephens DN, Mayne LV. [2006] Sp1 and NFkappaB pathways are regulated in brain in response to acute and chronic ethanol. Gene Brain Behave 5: 257-273.
13. Peng Z, Peng L, Fan Y, Zandi E, Shertzer HG, Xia Y. [2007] A critical role for ikappB kinase beta in metallothionein-1 expression and protection against toxicity. J Biol Chem 282: 21487-21496.
14. Brett K, Parker R, Wittenauer S, Hayashida K, Young T, Vincler M. [2007] Impact of chronic nicotine on sciatic nerve injury in the rat. J Neuroimmunol 186:37-44.
15. Noda M, Kariura Y, Amano T, Manago Y, Nishikawa K, Aoki S, Wada K. [2003] Expression and function of bradykinin receptors in microglia. Life Sci 72: 1573-1581.
16. Sharma SK, Yashpal K. Fundytus ME, Sauriol F, Henry JL, Coderre TJ. [2003] Alterations in brain metabolism by chronic morphine treatment: NMR study in rat CNS. Neurochem Res 28: 1369-1373.
17. Ebadi M, Sharma S, Wanpen S, Amornpan A. [2004] Coenzyme Q10 inhibits mitochondrial compelx-1 down-regulation and nuclear factor kappa B activation. J Cell Mol Med 8:213-222.
18. Sharma S and Ebadi M. [2005] Distribution kinetics of 18F-DOPA in weaver mutant mice. Brain Res Mol Brain Res 139:23-30.
19. Sharma S and Ebadi M.[2008] SPECT Neuroimaging in Translational Research of CNS Disorders. Neurochem Int 52:352-362.
20. Maharajan P, Maharajan V, Ravagnan G, Paino G. [2001] The wv/wv mouse: a model to study the ontogeny of dopaminergic transmission system as their role in drug addiction. Prog Neurobiol 64: 269-276.
21. Ebadi M, Brown-Borg H, Garrett S, Singh BB, Shavali S, Sharma SK. [2005] Metallothionein-mediated neuroprotection in genetically-engineered mouse models of Parkinson's disease. Brain Res Mol Brain Res 134:67-75.
22. Ebadi M, Sharma S, Ajjimaporn A, Maanum S. [2005] Weaver mutant mouse in progression of neurodegeneration in Parkinson's disease. In Parkinson's Disease P537, CRC Press, Boca Rota FL.
23. Ebadi M, Sharma S, Ghafourifar P, Brown-Borg H, Refaey HEl. [2005] Peroxinitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods in Enzymol 396: 276-298.
24. Ebadi M, Sharma S, Wanpen S, Shavali S. [2005] Metallothionein isoforms attenuate n Parkinson's Disease M Ebadi and R. Pfeiffer, CRC press New York pp 479-499.
25. Ebadi M, Wanpen S, Shavali S, Sharma S. [2005] Coenzyme Q10 stabilizes mitochondria in Parkinson's disease. Molecular Interventions in Life-Style-Related Diseases. Ed. Hiramatsu pp 127-153.
26. Murase S, Hayashi Y. [2002] Neuronal expression of macrophage colony stimulating factor in Purkinje cells and olfactory mitral cells of wild-type and cerebellar-mutant mice. Histochem J 34:84-95.
27. Douhou A, Debeir T, Michel PP, Stankoviski L, Oueghlani-Bouslama L, et al. [2003] Differential activation of astrocytes and microglia during post natal development of dopaminergic neuronal death in the weaver mouse. Brain Res. Dev Brain Res 145:9-17.
28. Sharma S and Ebadi M. [2004] An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples. J Neurosci Methods 137: 1-8.
29. Sharma S, Kheradpezhou M, Shavali S, Refaey HEI, Eken J, Hagen C, Ebadi M. [2004] Neuroprotective actions of coenzyme Q10 in Parkinson's disease. Method in Enzymol 382:488-509.
30. Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, Rafey EHI, Carlson EC. [2006] Therapeutic efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases. Curr Drug Targets 7: 1513-1529.
31. Ebadi M and Sharma S. [2003] Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinsons' disease. Antiox & Redox Signal 5: 319-335.
32. Sharma S and Ebadi M. [2003] Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid Redox Signal 5: 251-264.
33. Ebadi M and Sharma S. [2006] Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson's Disease. J Exp Biol and Med 231:1576-1583.
34. Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, et al. [2003] Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord 18: 928-932.
35. Piccini P, Pavese N, Hagell P, Reimer J, Bjorklund A, et al. [2005] Factors affecting the clinical outcome after neural transplantation in Parkinson's' disease. Brain 128: 2977-2986.
36. Sharma S, Refaey EHI, Ebadi M. [2006] Complex-1 activity and 18F-DOPA uptake in genetically-engineered mouse model of Parkinson's disease and the neuroprotective effect of coenzyme Q10. Brain Res Bull 70: 22-32.
37. Ajjimapron A, Phansuwan-Pujito P, Ebadi M, Govitrapong P. [2007] Zinc protects SK-N-SH cells from methamphetamine-induced α-Synuclein expression. Neurosci Lett 419:59-63.
38. Ajjimaporn A, Swinscoe J, Shavali S, and Ebadi M. [2005] Metallothionein provides zinc-mediated protective effects against Methamphetamine toxicity in SK-N-SH cells. Brain Res Bull 67:466-475.
39. Takeuchi A, Miyaishi PD, Kiuchi K, Isobe K. [2001] Macrophage colony stimulating factor is expressed in neuron and microglia after focal brain injury. J Neurosci Res 65: 38-44.
40. Suhara T. [2007] Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 1157: 100-111.
41. Banati RB. [2003] Neuropathological imaging: In-vivo detection of glial activation as a measure of disease and adaptive change in the brain.Br Med Bull 65:121-131.
42. Banati RB, Egensperger R, Maassen A, Hager G, Kreutzberg GW, Graeber MB. [2004] Mitochondria in activated microglia in vitro. J Neurocytol 33:535-541.
43. Zhang Y, Fong CC, Wong MS, Tzang CH, Lai WP, et al.[2005] Molecular mechanisms of survival and apoptosis in RAW-26647 macrophages under oxidative stress. Apoptosis 10: 545-556.
44. Sangchot P, Sharma S, Chetsawang B, Porter J, Govtrapong P, Ebadi M. [2002] Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 24: 143-153.
45. Koocumchoo P, Govitrapong P, Sharma S, Ebadi M. [2006] Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. Mol Neurosci 28: 125-142.
46. Akahoshi N, Marushima YL, Himi T, Ishizaki Y, Ishii Y. [2007] Increased expression of the lysosomal protease cathapsin S in hippocampal microglia following kainate-induced seizures. Neurosci Lett 429:136-141.
47. Guinta B, Ehrhart J, Townsend K, Sun N, Vendrame M, et al. [2004] Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res. Bull 64:165-170.
48. de Simone R, Ajimone-cat MA, Carnevale D, Minghetti L. [2005] Activation of alpha 7-nicotinic acetylcholine receptor by nicotine selectively up regulates cycloxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 25:2(1) 4.
49. Shytle RD, Mori T, Townsend K, vendrame K, Sun N, et al. [2004] Cholinergic modulation of microglial activation by alpha 7-nicotinic receptors. J Neurochem 89: 337-343.
50. Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, et al. [2007] Neuroprotective effects of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 26: 79-89.
51. Brett K, Parker R, Wittenauer S, Hayashida K, Young T, Vincler M. [2007] Impact of chronic nicotine on sciatic nerve injury in the rat. J Neuroimmunol 188:37-44.
52. Cagnin A, Gerhard A, Banati RB. [2002] In-Vivo Imaging of Neuroinflammation. Eur Neuropharmacol 12:581-586.
53. Cagnin A, Kassiou M, Meikle SR, Banati RB. [2007] Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 4: 443-452.
54. Gerhard G, Banati RB, Goerres GB, Cagnin A, Myers R, et al. [2003] [11C](R)-PK11195 in progressive supranuclear palsy. Mov Disorder 21: 89-93.
55. Gerhard A, watts J, Trender-Grehard I, Turkheimer F, Banati RB, et al. [2004] In-vivo imaging of microglial activation with [11C] (R) PK-11195 PET in corticobasal degeneration. Mov Disord 19: 1221-1226.
56. Gerhard A, Pavrse N, Hottan G, Turkheimer F, ESM, hammers A, et al. [2006] In-vivo imaging of microglial activation with [11C] (R) -PK-11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 21: 404-412.
57. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. [2006] In vivo imaging of microglial activation with [11C](R)-PK-11195 in progressive supranuclear palsy. Mov Disord 21: 89-93.
58. Wiley CA, Lopresti BJ, Becker JT, Boada F, Lopez OL, et al. [2006] Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol 12: 262-271.
59. Hammoud DA, Endres CJ, Chander AR, Guilarte TR, Wong DF, et al. [2005] Imaging glial cells activation with [11C] (R)-PK-11195 in patients with AIDS. J Neurovirol 11: 346-355.
60. Kropfeller MA, Boelaard R, Schuitemaker A, Folkersma H, vanBerckel BN, Lammertsma AA. [2006] Evaluation of reference tissue models for the analysis of [11C] (R) PK-11195 studies. J Cerebral Blood Flow and Metab 26: 1431-1441.
61. Kropfeller MA, Boelaard R, vanBerckel BN, Schuitemaker A, Kloet RW, et al. [2007] Evaluation of reference regions for (R) [11C] PK-11195 studies in Alzheimer's disease and mild cognitive impairment. J Cereb Blood Flow and Metab 26: 1431-1441.
62. Price CJS, Wang D, Menon DK, Guadagno JV, Cleij M, et al. [2006] Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 37:1749-1753.
63. Tai YF, Pavese N, Gehard A, Tabrizi AJ, Barker RA, Brooks DJ, Piccini P. [2007] Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130: 1759-1766.
64. Turkhemier FE, Edison P, Pavese N, Roncaroli F, Anderson AN, et al. [2007] Reference and target region modeling of [11C] -(R) -PK-11195 brain studies. J Nucl Med 48: 156-167.
65. Kannan S, Saadani-Makki F, Muzik O, Chakraborty P, Mangner TJ, et al. [2007] Microglial activation in perinatal rabbit brain induced by intrauterine inflammation: detection with [11C] (R) PK11195 and small animal PET. J Nucl Med 48: 946-954.
66. Vowinckel E, Reutens D, Becher B, verge G, Evans J, Qwens T, Antel JP. [1997] PK-11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental immune encephalomyelitis. J Neurosci Res 50: 345-353.
67. Cicchetti F, Brownell Al, Williams K, Chen YI, Livni E, Isacson O. [2002] Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European J Neurosci 15:991-998.
68. Sharma S, Carlson E, Ebadi M. [2003] Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol 76:563-571.
69. McGuire SO, Ling ZD, Lipton JW, Sortwell CI, Collier TJ, Carvey PM. [2001] Tumor necrosis factor alpha ins toxic to embryonic mesencephalic dopaminergic neurons. Exp Neurol 169: 219-230.
70. Klongpanichapak S, Govtrapong P, Sharma S, Ebadi M. [2006] Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res 31: 303-311.
71. Chagkutip J, Vaughan RA, Govitrapong P, Enadi M. [2003] 1-Methyl-4-phenylpyridinium-induced down-regulation of dopamine transporter function correlates with reduction in dopamine transporter cell surface expression. Biochem Biophysi Res Commun 311:49-54.
72. Chagkutip J, Govitrapong P, Klongpanichapak S, Ebadi M. [2005] Mechanism of 1-methyl-4-phynylpyridinium-induced dopamine release from PC12 cells. Neurochem Res 30:633-639.
73. Xie T, Tong L, McCann UD, Yuan J. Becker KG, Mechan AO, et al. [2004] Identification and characterization of metallothioneins-1 and 2 gene expression in the context of (+/-) 3,4-methylene dioxy methamphetamine-induced toxicity to brain dopamniergic neurons. J Neurosci 24: 7043-7050.
74. Yang Z, Yang S, Qian SY, Hong JS, Kadiiska MB, et al. [2007] Cadmiium-induced toxicity in rat primary mid-brain neuroglia cultures: Role of oxidative stress from microglia. Toxicol Sci 98: 488-494.
75. Butcher HL, Kennette WA, Collins O, Zalups RK, Koroparnick J. [2004] Metallothionein mediates the level and activity of nuclear factor kappa B in murine fibroblasts. J Pharmacol Exp Ther 310:589-598.
76. Itoh N, Kimura T. [2007] Cytokine-induced metallothionein expression and modulation of cytokine expression by metallothionein] Yakgaki Zasshi 127: 685-694.
77. Wanpen S, Govitrapong P, Shavali S, Sangchot P, Ebadi M. [2004] Salsolinol, a dopamine-derived tetrahydroisoquinoline, induces cell death by causing oxidative stress in dopaminergic SH-SY5Y cells, and the said effect is attenuated by metallothionein. Brain Res 1005: 67-76.
78. Wanpen S, Kooncumchoo P, Shavali S, Govitrapong P, Ebadi M. [2007] Salsolinol, an endogenous neurotoxin, activates JNK and NFkappaB signaling pathways in human neuroblastoma cells. Neurochem Res 32: 443-450.
79. Vasto S, Mocchegiani E, Malavolta M, Cuppari I, Listi F, et al. [2007] Zinc and inflammatory/immune response in aging. Ann N Y Acad Sci 1100:111-122.
80. Ono S, Ishizaki Y, Tokuda E, Tabata K, Asami S, Suzuki T. [2007] Different patterns in the induction of metallothionein mRNA synthesis among isoforms after acute ethanol administration. Biol Tracer Element Res 115: 147-156.
81. Penkowa M. [2006] Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS Journal 273: 1857-1870.
82. Boess F, Ndikum-Moffor FM, Boeslste UA, Roberts SM. [2000] Effects of cocaine and its oxidative meytabolites on mitochondrial respiration and generation of reactive oxygen species. Biochem Biopharmacol 60:615-623.
83. Dietrich JB, Poirrier R, Aunis D, zwiller J. [2004] Cocaine down-regulates the expression of mitochondrial genome in rat brain. Ann N Y Acad Sci 1025:345-350.
84. Dietrich JB, Mangeol A, Revel MO, Burgun C, Aunis D, Zwiller J. [2005] Acute or repeated Cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. Neuropharmacol 48:965-974.
85. Imam SZ, Duhart HM, Skinner JT, Ali SF. [2005] Cocaine induces a differential dose-dependent alteration in the expression profile of immediate early genes, transcriptional factors, and caspases in PC12 cells. A possible mechanism of neurotoxic damage in cocaine addiction. Ann N Y Acad Sci 1053: 482-490.
86. Ang E, Chen Z, Zagouras P, Magna H, Holland J, Schaeffer E, Nestlet EJ [2001] Induction of nuclear factor kappa B in nucleus accumbens by chronic cocaine administration. J Neurochem 79:221-224.
87. Hargrave BY, Tiangco DA, Lattanzio FA, Beebe SJ. [2003] Cocaine, not morphine, causes the generation of reactive oxygen species and activation of NF-kappa B in transiently cotransfected heart cells. Cardiovasc Toxicol 3: 141-151.
88. Arango JC, Simonds P, Brettle RP, Bell JE. [2004] Does drug abuse influence the microglial response in AIDS and HIV encephalitis? AIDS 18:S69-S74.
89. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. [2004] kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 309:600-606.
90. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Petersen PK. [2006] Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta-1.Int Immunopharmacol 6: 1029-1033.
91. Imam SZ, el Yazal J, Newport DJ, Itzhak Y, Cadet JL et al. [2001] Methamphetamine-induced dopaminergic neurotoxicity. Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci 939:366-380.
92. Jayanthi S, Deng X, Noailles PH, Ladenheim B, abd cadet JL. [2004] Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18: 238-251.
93. Darvesh AS, Yamamoto BK, Gudelsky GA. [2005] Evidence for the involvement of nitric oxide in 3, 4-methylene dioxymethamphetamine-induced serotonin depletion in the rat brain. J Pharmacol Exp Ther 312:694-701.
94. Virmani A, Gaetani F, Imam S, Binienda Z, Ali S. [2003] Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity. Ann N Y Acad Sci 993:197-207.
95. Hanson GR, Rau KS, Flekenstein AE. [2004] The amphetamine experience: A NIDA Partnership. Neuropharmacol 47: S92-100.
96. Sulzer D, Sonders MS, Poulsen NW, Galli A. [2005] Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 5:406-433.
97. Bowyer JF, Ali S. [2006] High doses of Methamphetamine that cause disruption of the blood brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60:521-532.
98. Thomas DM, Waker PD, Benjamins JA, Geddes TJ, Kuhn DM. [2004] Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Therap 311:1-7.
99. Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, et al. [2005] Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res 8: 63-80.
100. Cui Y, Chen Y, Zhi JL, Guo RX, Feng JO, Chen PX. [2006] Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinocicpetive tolerance. Brain Res 1069:235-243.
101. Baraona E, Zeballos GA, Shoichet L, Mak KM, Lieber CS. [2002] Ethanol consumption increases nitric oxide production in rats and its peroxynitrite-mediated toxicity is attenuated by polyethyl phsophatidylcholine. Alcohol Clin Exp Res 26:883-889.
102. Narita M, Miyoshi K, Narita M, Suzuki T. [2007] Involvement of microglia in the ethanol-induced neuropathic pain-like state in the rat. Neurosci lett 414: 21-25.
103. Crews F, Nixon K, Kim D, Joseph J, Suhkitt-Hale B, Qin L, Zou J. [2006] BHT blocks NF-kappa B activation and ethanol-induced brain damage. Alcohol Clin Exp Res 30: 1938-1949.
104. Lee H, Jeong J, Son E, Mosa A, Cho GH, et al. [2004] Ethanol selectively modulates inflammatory activation signaling of brain microglia. J Neuroimmunol 156: 88-95.
105. Suk K. [2007] Microglial signal transduction as a target of alcohol action in the brain. Curr Neurovasc Res 4:131-142.
106. Suuronen T, Huuskoned J, Pihlaja R, Kyrylenko S, Salminen A. [2003] Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 87:407-416.
107. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, et al. [2006] Microglial alpha 7 nicotine acetylcholine receptors drive a phsopholipase C/IP3 pathway and modulate the cell activation towards the neuroprotective role. J Neurosci Res 83: 1461-1470.
108. Bollimuntha S, Singh BB, Shavali S, Sharma S, and Ebadi M. [2005] TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuropbastoma cells. J Biol Chem 280:2132-2140.
109. Klongpanichapak S, Phansuwan-Pujito P, Ebadi M, Govitrapong P. [2007] Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. J Pineal Res 43: 65-73.
110. Shavali S, Ren J, Ebadi M. [2003] Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity. Neurosci Lett 340: 79-82.
111. Shavali S, Carlson CS, Swinscoe JC, Ebadi M. [2004] 1-benzyl-1, 2, 3, 4-tetrahydroisoquinoline, a parkinsonism-inducing toxin increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. J Neurosci Res 76: 563-571.
112. Shavali S, Combs C, Ebadi M. [2006] Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture. Relevance to Parkinson's disease. Neurochem Res 31: 85-94.
113. Sharma S, Ebadi M. [2008] Therapeutic Potential of Metallothioneins in Parkinson's disease. In New Research on Parkinson's Disease. Eds T.M Hahn and Julian Werner, Chapter-1 pp 1-41. Nova Science Publishers USA.